ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes (DSS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03093636
Recruitment Status : Recruiting
First Posted : March 28, 2017
Last Update Posted : August 7, 2018
Sponsor:
Collaborators:
TypeZero Technologies, Inc.
Novo Nordisk A/S
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
DexCom, Inc.
Information provided by (Responsible Party):
Stacey Anderson, University of Virginia

Brief Summary:
The purpose of this study is to reduce the frequency of hypoglycemia and severe hypoglycemic events in subjects who use insulin pens to treat their Type 1 Diabetes Mellitus (T1DM). Hypoglycemia is the number one fear of many individuals and families with someone who has type 1 diabetes, and this fear often prevents optimal glycemic control. It is expected that this protocol will yield increased knowledge about using a decision support system to help control the glucose level.

Condition or disease Intervention/treatment Phase
Type1 Diabetes Mellitus Device: Continuous Glucose Monitor (CGM)+Decision Support System (DSS) Other: Continuous Glucose Monitor (CGM) alone Not Applicable

Detailed Description:

This study is a 12-week parallel group multi-center randomized trial designed to compare CGM+DSS with CGM alone. The DSS to be implemented contains a "smart" bolus advisor that adjusts the size of correction insulin boluses based on short term blood glucose predictions. It is able to complete this function by evaluating CGM values, insulin usage and carbohydrate intake record. It also contains an exercise advisor, a bedtime advisor, hypoglycemia risk and long-term tracker of HbA1c.

inControl-Advice, a smart-phone based medical software platform, is designed to provide advice to users. It receives data from an insulin pen and then adjustments the insulin delivery every 5 minutes. The system provides a series of real-time alerts and on-demand advice, for both dosing of insulin and ingestion of carbohydrates, based on data collected from T1DM patients (i.e. carbohydrate consumption, insulin injected, CGM) and inConrol Cloud analytics.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes
Actual Study Start Date : April 17, 2017
Estimated Primary Completion Date : December 31, 2018
Estimated Study Completion Date : December 31, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1
Drug Information available for: Dextrose

Arm Intervention/treatment
Experimental: Continuous Glucose Monitor (CGM)+Decision Support System (DSS)
Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App, study insulin, and study CGM at home for 12 weeks.
Device: Continuous Glucose Monitor (CGM)+Decision Support System (DSS)
Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App and a study CGM at home for 12 weeks. The DSS contains a "smart" bolus advisor that adjusts the size of the correction insulin boluses based on short-term blood glucose predictions. It is able to complete this function by evaluating CGM values, insulin usage and carbohydrate intake record. It also contains an exercise advisor, a bedtime advisor, hypoglycemia risk and long-term tracker of HbA1c. Subjects will use study basal and bolus insulin during the study.

Placebo Comparator: Continuous Glucose Monitor (CGM) alone
Continuous Glucose Monitor (CGM) alone study participants will use study insulin and the study CGM alone at home for 12 weeks.
Other: Continuous Glucose Monitor (CGM) alone
Continuous Glucose Monitor (CGM) alone study participants will use a study CGM at home for 12 weeks. Subjects will use study basal and bolus insulin during the study.




Primary Outcome Measures :
  1. Increased % time within target range [ Time Frame: 12 weeks ]
    The primary efficacy outcome is increased % time within target range defined as CGM readings of 70-180 mg/dL during the day and 80-140 mg/dL overnight.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years to 100 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Willingness to provide informed consent
  2. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year and using insulin for at least 1 year
  3. Using basal and meal insulin (NovoLog® [insulin aspart], Humalog® [insulin lispro] or Apidra® [insulin glulisine]) for Intensive Insulin Therapy including carbohydrate counting and use of pre-defined parameters for glucose goal, carbohydrate ratio, and insulin sensitivity factor for at least 1 month.

    a. Acceptable basal insulin regimens include: i. Lantus® (insulin glargine) 100U/mL once or twice daily ii. Levemir® (insulin detemir) 100U/mL once or twice daily iii. Tresiba® (insulin degludec) 100U/mL once daily

  4. Age ≥15.0 years old
  5. Willingness to use the study basal insulin (Tresiba® [insulin degludec]) and meal insulin (NovoLog® [insulin aspart]) for the duration of the study.
  6. Willingness to use the home or DSS-optimized carbohydrate counting parameters for all meal dosing and enter the information into the inControl APP (for CGM+DSS group).
  7. For females, not currently known to be pregnant
  8. If female and sexually active, must agree to use a highly effective form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all premenopausal women who are not surgically sterile. Subjects who become pregnant will be discontinued from the study. Also, subjects who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.
  9. Ability to access the Internet to provide data to the clinical team or to travel to the research center so that the study equipment can be downloaded.
  10. Ability to have 3G or Wi-Fi to be able to use the DSS smart bolus calculator and advice given (i.e. sleep, exercise).
  11. Demonstration of proper mental status and cognition for the study
  12. Investigator has confidence that the subject can successfully operate all study devices and is capable of adhering to the protocol
  13. If on a non-insulin hyperglycemic therapy, stability on that therapy for the prior 3 months and willingness not to alter the therapy for the study duration.

Exclusion Criteria:

  1. Medical need for chronic acetaminophen
  2. Use of any medication that at the discretion of the clinical protocol chair is deemed to interfere with the trial.
  3. Current treatment of a seizure disorder.
  4. Coronary artery disease or heart failure, unless written clearance is received from a cardiologist.
  5. Hemophilia or any other bleeding disorder
  6. A known medical condition, which in the opinion of the investigator or designee, would put the participant or study at risk such as the following examples:

    1. Inpatient psychiatric treatment in the past 6 months
    2. Presence of a known adrenal disorder
    3. Abnormal liver function test results (Transaminase >3 times the upper limit of normal)
    4. Abnormal renal function test results (calculated GFR <60 mL/min/1.73m2).
    5. Active gastroparesis requiring medical therapy
    6. Uncontrolled thyroid disease (TSH undetectable or >10 mlU/L).
    7. Abuse of alcohol or recreational drugs
    8. Infectious process not anticipated to be resolved prior to study procedures (e.g. meningitis, pneumonia, osteomyelitis, deep tissue infection).
    9. Uncontrolled arterial hypertension (Resting diastolic blood pressure >100 mmHg and/or systolic blood pressure >180 mmHg).
    10. Uncontrolled microvascular complications such as current active proliferative diabetic retinopathy defined as proliferative retinopathy requiring treatment (e.g. laser therapy or VEGF inhibitor injections) in the past 12 months.
  7. A recent injury to body or limb, muscular disorder, use of any medication, any carcinogenic disease, or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the protocol.
  8. Current use of the following drugs and supplements:

    k. Regular acetaminophen user, or not willing to suspend acetaminophen 24 hours before and during the entire length of the trial l. Oral steroids m. Any other medication that the investigator believes is a contraindication to the subject's participation

  9. Participation in another pharmaceutical or device trial at the time of enrollment or during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03093636


Contacts
Contact: Jessica Robic 434-982-3459 jlr8yq@virginia.edu
Contact: Jennifer Pinnata, RN 434-982-0631 jp3te@virginia.edu

Locations
United States, California
Stanford University Recruiting
Stanford, California, United States, 94304
Contact: Bruce Buckingham, MD    650-723-5791    bbendo@stanford.edu   
Contact: Ellen Ambers, BSN, RN, PHN, CDE    650-723-8163    eambers@stanford.edu   
Principal Investigator: Bruce Buckingham, MD         
United States, New York
Icahn School of Medicine at Mt. Sinai Recruiting
New York, New York, United States, 10029
Contact: Carol Levy, MD, CDE    212-241-9089    Carol.Levy@mssn.edu   
Contact: Camilla Levister, ANP-C, MS    212-241-5177    Camilla.Levister@mssm.edu   
Principal Investigator: Carol Levy, MD, CDE         
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22903
Contact: Stacey M. Anderson, MD    434-982-0945    sg4c@virginia.edu   
Contact: Jess Robic    434-982-3459    jlr8yq@virginia.edu   
Principal Investigator: Stacey M. Anderson, MD         
Sub-Investigator: Sue A. Brown, MD         
Sponsors and Collaborators
Stacey Anderson
TypeZero Technologies, Inc.
Novo Nordisk A/S
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
DexCom, Inc.
Investigators
Principal Investigator: Stacey M. Anderson, MD University of Virginia Center for Diabetes Technology

Responsible Party: Stacey Anderson, Principal Investigator, University of Virginia
ClinicalTrials.gov Identifier: NCT03093636     History of Changes
Other Study ID Numbers: 19634
DP3DK101055 ( U.S. NIH Grant/Contract )
U1111-1191-3911 ( Other Identifier: Universal Trial Number )
First Posted: March 28, 2017    Key Record Dates
Last Update Posted: August 7, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: pending

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No

Keywords provided by Stacey Anderson, University of Virginia:
Type 1 Diabetes Mellitus (T1DM)
Continuous Glucose Monitor (CGM)
Multiple Daily Injections (MDI)
Insulin Pen
inControl Advice
Decision Support System (DSS)

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Hypoglycemic Agents
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin, Globin Zinc
Insulin
Physiological Effects of Drugs